John K. Scott Jr. - 27 Nov 2023 Form 4 Insider Report for NAVIDEA BIOPHARMACEUTICALS, INC.

Role
Director, 10%+ Owner
Signature
Gioia Gentile on behalf of John K. Scott, Jr., by power of attorney
Issuer symbol
N/A
Transactions as of
27 Nov 2023
Net transactions value
+$4,028,900
Form type
4
Filing time
05 Dec 2023, 18:26:20 UTC
Previous filing
30 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NAVB Series G Redeemable Preferred Stock Other -2,270 -100% 0 27 Nov 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NAVB Series I Convertible Preferred Stock Other $2,400,000 -2,400 -100% $1000.00* 0 27 Nov 2023 Common Stock 15,000,000 $0.1600 Direct F1, F2
transaction NAVB Series J Convertible Preffered Stock Other $6,428,900 +64,289 $100.00* 64,289 27 Nov 2023 Common Stock 61,816,346 $0.1040 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Navidea entered into a Loan and Exchange Agreement with the Reporting Person, pursuant to which he surrendered 2,270 shares of Series G Preferred Stock, par value $.001 per share plus accrued and unpaid dividends thereon, and 2,400 shares of Series I Preferred Stock, par value $.001 per share, and other consideration, in exchange for 64,289 shares of Series J Preferred Stock, par value $.001.
F2 Series J Convertible Preferred Stock, par value $.001 per share, is convertible at any time and has no expiration date.

Remarks:

Exhibit 24: John K. Scott, Jr. Power of Attorney